20 December 2017 - Patients in England and Wales will now be able to access Takeda’s myeloma treatment Ninlaro on the NHS, after cost regulators cleared its use through the Cancer Drugs Fund.

Ninlaro (ixazomib), a proteasome inhibitor and the first oral drug of its kind, has been recommended by the National Institute for Health and Care Excellence for use in combination with lenalidomide (Revlimid) and dexamethasone for patients with myeloma who have received two or three prior treatments.

A number of trials have shown that patients treated with a novel three-drug combination may live longer without their disease worsening, compared to two-drug combinations, Takeda noted.

Read Pharma Times article